Special channel feed – Endpoints News

Special channel feed

Special report 2023: Meet 20 women reshaping biopharma

Last year

Biopharma leaders paving the way for LGBTQ+ scientists, patients, entrepreneurs and C-suites

Last year

The 20(+2) under 40: Your guide to the next generation of biotech leaders

Last year

The E100: Extending runways, dumping drugs, factoring in a banking crisis and grappling with the IRA — there's a lot for biotech execs to deal with

3 years ago

Who’s spending and who’s cutting from Big Pharma’s $127B R&D budget? Here are the top 15 players

3 years ago

Every drug approved in 2022: A year of fewer new products, but gene therapy firsts and new blockbusters

3 years ago

WIB22: Hear from our 2022 Women in Biopharma R&D honorees, and catch our panel on empowering women

3 years ago

WIB22: Amber Salzman had few options when her son was diagnosed with a rare genetic disease. So she created a better one

3 years ago

WIB22: Leading NK cell researcher reflects on roots in Iran, the UK and Texas

3 years ago

WIB22: Chasing after ever-evolving science takes a drug hunter across the pond

3 years ago

WIB22: Suma Krishnan co-founded a company to develop a treatment for ‘the worst disease you’ve never heard of’

3 years ago

WIB22: She reshaped migraine science and led key trials for new drugs, but Sheena Aurora isn’t done

3 years ago

Special report 2022: Meet 20 women blazing trails in biopharma R&D

3 years ago

The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies

3 years ago

15 leaders giving voice and visibility to the LGBTQ community in biopharma

3 years ago

The Endpoints R&D 15: How many blockbusters does $124B buy the biggest spenders in drug research? (Not enough)

4 years ago

The 20(+1) under 40: Your guide to the next generation of biotech leaders

4 years ago

The 2022 top 100 biopharma investors: A look back on boom times

4 years ago

2021's NDA list includes some extraordinary accomplishments in year #2 of the pandemic

4 years ago

Endpoints editors select the top trends of 2022: M&A looks hot as IPOs wane, it's time to see some hard data on AI and can accelerated approval remain intact?

4 years ago

Video: Hear from Endpoints' 2021 Women in Biopharma R&D honorees and listen in on our panel discussion on breaking the glass ceiling

4 years ago

Special report: Meet 20 extraordinary women who are supercharging biopharma R&D

4 years ago

The Endpoints 100 gives a C-suite thumbs down on 'crippling' price proposals and Aduhelm. Plus: Is anyone going to JP Morgan?

4 years ago

The Endpoints 11: They've got mad money and huge ambitions. It's time to go big or go home

4 years ago

First page Previous page 123 4 Next page Last page